#ASH20: Loxo and Eli Lilly show off PhI/II data for their BTK inhibitor in mantle cell lymphoma

#ASH20: Loxo and Eli Lilly show off PhI/II data for their BTK inhibitor in mantle cell lymphoma

Source: 
Endpoints
snippet: 

ASH is back and Loxo is primed and ready to present new data that they think will be quite exciting.

The Lilly-owned company is announcing results from a Phase I/II trial on its LOXO-305 program, and Saturday afternoon they detailed data in patients with mantle cell lymphoma (MCL) and other non-Hodgkin lymphomas. It’s the first of two expected presentations on the drug, as researchers are planning on releasing results from another patient population within the trial Monday.